SCHEMBL288477

SCHEMBL288477

[CH2]Cc1nc2ccccc2s1

nearest known ligand 0.66

Predicted protein targets (top 20)

geneUniProtsupporting neighboursconfidence
UBE2T Q9NPD8 1/20 0.66
ASIC3 Q9UHC3 1/20 0.66
SMN1; SMN2 Q16637 7/20 0.56
RAB9A P51151 6/20 0.56
NPC1 O15118 5/20 0.56
L3MBTL1 Q9Y468 2/20 0.56
MAPK1 P28482 1/20 0.56
MAPT P10636 4/20 0.53
HTT P42858 2/20 0.51
CYP1A2 P05177 2/20 0.51
ALOX15 P16050 1/20 0.51
CYP2C19 P33261 1/20 0.51
PDE10A Q9Y233 1/20 0.51
KMT2A Q03164 4/20 0.50
HPGD P15428 3/20 0.50
MEN1 O00255 2/20 0.50
ALDH1A1 P00352 2/20 0.50
HSD17B10 Q99714 1/20 0.50
PKM P14618 1/20 0.50
KDM4E B2RXH2 1/20 0.49

Click a target to see other patent compounds predicted against it — the reverse direction, in place.

Similar compounds — the chemically nearest patent molecules

Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.

Compoundsimilaritytop predictedshared targets
SCHEMBL8904885 0.84 UBE2T (0.61) UBE2TASIC3SMN1; SMN2RAB9ANPC1
SCHEMBL3117628 0.83 UBE2T (0.66) UBE2TASIC3SMN1; SMN2RAB9ANPC1
SCHEMBL19372016 0.83 UBE2T (0.70) UBE2TASIC3SMN1; SMN2RAB9ANPC1
SCHEMBL226465 0.83 UBE2T (0.70) UBE2TASIC3SMN1; SMN2RAB9ANPC1
SCHEMBL2047532 0.81 SMN1; SMN2 (0.62) UBE2TASIC3SMN1; SMN2RAB9ANPC1
Bromide SCHEMBL7601035 0.81 UBE2T (0.68) UBE2TASIC3SMN1; SMN2RAB9ANPC1
SCHEMBL5537342 0.80 SMN1; SMN2 (0.60) UBE2TASIC3SMN1; SMN2RAB9ANPC1
SCHEMBL16397518 0.79 UBE2T (0.66) UBE2TASIC3SMN1; SMN2RAB9ANPC1
Fluoride SCHEMBL7600822 0.79 UBE2T (0.66) UBE2TASIC3SMN1; SMN2RAB9ANPC1
SCHEMBL322456 0.79 UBE2T (0.66) UBE2TASIC3SMN1; SMN2RAB9ANPC1

Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.

Patent provenance — the patents this molecule appears in, and who filed them

Claimed or disclosed in 100 patents — showing the first 20. claimed = in the patent's claims; disclosed = body only.

PatentTitleAssigneePublishedPriorityFilingCountryStatus
EP-2091929-A1 AGENTS THAT DISRUPT CELLULAR REPLICATION AND THEIR USE IN INHIBITING PATHOLOGICAL CONDITIONS The European Molecular Biology Laboratory (DE) 2009-08-26 EP claimed
CN-101421257-A Agents that disrupt cellular replication and their use in inhibiting pathological conditions EUROPEAN MOLECULAR BIOLOGY LAB EMBL (DE) 2009-04-29 CN claimed
WO-2007107352-A1 AGENTS THAT DISRUPT CELLULAR REPLICATION AND THEIR USE IN INHIBITING PATHOLOGICAL CONDITIONS THE EUROPEAN MOLECULAR BIOLOGY LABORATORY (DE) 2007-09-27 WO claimed
CN-1061213-C Combating fish parasites BAYER AG (DE) 2001-01-31 CN claimed
US-5504081-A ADMINISTERING NICOTINERGIC ACETYLCHOLINE RECEPTOR ANTAGONISTS AND AGONISTS BAYER AKTIENGESELLSCHAFT (DE) 1996-04-02 US claimed
US-4692529-A Method for synthesizing a magenta coupler by selectively etherifying 4-hydroxy-5-pyrazolone KONISHIROKU PHOTO INDUSTRY CO., LTD. (JP) 1987-09-08 US claimed
EP-4261830-A1 NOVEL PEPTIDOMIMETIC COMPOUND AND DESIGN Oita University Institute of Advanced Medicine, Inc. (JP) 2023-10-18 EP disclosed
CN-116615423-A Novel peptidomimetic compounds and design 株式会社大分大学先端医学研究所 2023-08-18 CN disclosed
US-11661410-B2 Tricyclic compounds as histone methyltransferase inhibitors GLOBAL BLOOD THERAPEUTICS, INC. (US) 2023-05-30 US disclosed
US-11584734-B2 Tricyclic compounds as histone methyltransferase inhibitors GLOBAL BLOOD THERAPEUTICS, INC. (US) 2023-02-21 US disclosed
US-20230002351-A1 TRICYCLIC COMPOUNDS AS HISTONE METHYLTRANSFERASE INHIBITORS GLOBAL BLOOD THERAPEUTICS, INC. 2023-01-05 US disclosed
US-20200361896-A1 TRICYCLIC COMPOUNDS AS HISTONE METHYLTRANSFERASE INHIBITORS GLOBAL BLOOD THERAPEUTICS, INC. 2020-11-19 US disclosed
CN-111372927-A Tricyclic compounds as histone methyltransferase inhibitors 全球血液疗法股份有限公司 2020-07-03 CN disclosed
EP-0368946-A4 1,2-DIOXETANES. QUEST SYSTEMS INC (US) 1990-05-14 EP disclosed
WO-1989006226-A1 SYNTHESIS OF 1,2-DIOXETANES AND INTERMEDIATES THEREFOR QUEST SYSTEMS, INC. (US) 1989-07-13 WO disclosed
CN-88101027-A Growth promoting composition and preparation method thereof 1988-08-31 CN disclosed
US-4692529-A Method for synthesizing a magenta coupler by selectively etherifying 4-hydroxy-5-pyrazolone KONISHIROKU PHOTO INDUSTRY CO., LTD. (JP) 1987-09-08 US disclosed
EP-0215355-A2 Erythromycin derivative and process for preparing the same KITASATO KENKYUSHO (JP) 1987-03-25 EP disclosed
EP-0213617-A2 Digestive tract contractile motion stimulant KITASATO KENKYUSHO (JP) 1987-03-11 EP disclosed
US-4399075-A Process for producing chlorinated phenoxytoluene derivatives ASAHI CHEMICAL COMPANY, LIMITED (JP) 1983-08-16 US disclosed

Patent text — is the patent's own abstract consistent with the prediction?

For each of this compound's patents that has machine-readable text (4 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.

PatentTitleText reads most aboutPredicted target · text-rank
US-20230002351-A1 TRICYCLIC COMPOUNDS AS HISTONE METHYLTRANSFERASE INHIBITORS EHMT1, EHMT2, BMI1 UBE2T 989/4885ASIC3 4294/4885SMN1; SMN2 400/4885
US-11661410-B2 Tricyclic compounds as histone methyltransferase inhibitors EHMT1, EHMT2, BMI1 UBE2T 989/4885ASIC3 4294/4885SMN1; SMN2 400/4885
US-11584734-B2 Tricyclic compounds as histone methyltransferase inhibitors EHMT1, EHMT2, BMI1 UBE2T 1382/4885ASIC3 4189/4885SMN1; SMN2 349/4885
US-20200361896-A1 TRICYCLIC COMPOUNDS AS HISTONE METHYLTRANSFERASE INHIBITORS EHMT1, EHMT2, BMI1 UBE2T 1382/4885ASIC3 4189/4885SMN1; SMN2 349/4885

“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.